POSITION
Lead
BOARD
BOD member until April 2017
EXIT
The company did an IPO (NYSE) in May 2017
Zymeworks is a computational biotechnology company researching and developing next-generation protein therapeutics. Zymeworks leverages proprietary insight into structure-function relationships generated by its platforms to optimize the efficacy and potency of protein therapeutics. Zymeworks is focused on developing a biotherapeutics pipeline through strategic collaborations and internal research programs. The company did an IPO (NYSE) in May 2017.